PLUS1
Best deals to access real time data! |
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Genprex Inc | GNPX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.0% | 0.2891 | 0.00 | 0.00 | 0.00 | 0.2891 | 08:44:32 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 0.2725 | 0.32 | 0.0475 | 14.84% | - | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.00 | USD |
Genprex Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 5.50M | 19.02M | $ -12.37M | -0.89 | - | 18.40M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | 1.00 | 3.90% |
Genprex News
| Date | Time | Source | News Article |
|---|---|---|---|
| 11/22/2019 | 16:05 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 11/22/2019 | 15:59 | Edgar (US Regulatory) | Small Company Offering and Sale of Securities Without.. |
| 11/22/2019 | 09:23 | Edgar (US Regulatory) | Statement of Ownership (sc 13g) |
| 11/21/2019 | 16:07 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) |
| 11/20/2019 | 11:15 | Business Wire | Genprex Announces $1.26 Million Registered Direct Offering |
| 11/19/2019 | 08:00 | Business Wire | Genprex Reports Positive Preclinical Data for the Treatment.. |
| 11/14/2019 | 12:10 | Edgar (US Regulatory) | Quarterly Report (10-q) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GNPX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.275 | 0.33 | 0.26 | 0.2908137 | 388,861 | 0.0141 | 5.13% |
| 1 Month | 0.4578 | 1.09 | 0.2403 | 0.4861118 | 1,108,076 | -0.1687 | -36.85% |
| 3 Months | 0.915 | 1.09 | 0.2403 | 0.4933503 | 415,485 | -0.6259 | -68.4% |
| 6 Months | 1.41 | 1.5047 | 0.2403 | 0.5538547 | 223,407 | -1.12 | -79.5% |
| 1 Year | 1.19 | 2.49 | 0.2403 | 0.7164855 | 132,110 | -0.9009 | -75.71% |
| 3 Years | 4.69 | 19.4499 | 0.2403 | 4.77 | 139,600 | -4.40 | -93.84% |
| 5 Years | 4.69 | 19.4499 | 0.2403 | 4.77 | 139,600 | -4.40 | -93.84% |
Genprex Description
| Genprex Inc is a U.S.-based clinical-stage gene therapy company. It is engaged in developing a new approach to treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells and modulates the immune response against cancer cells. |
